M. Lassus

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun et al. · Journal of Clinical Oncology · 2001 · 1K citations · Full text

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

W. Eiermann, Stefan Paepke, Justus Appfelstaedt et al. · Annals of Oncology · 2001 · 712 citations

Surgical Oncology, Breast Oncology, Preoperative Treatment +7

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

M. Gershanovich, H.A. Chaudri, Diogo Ayres‐de‐Campos et al. · Annals of Oncology · 1998 · 263 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +11

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

T.R. Jeffry Evans, E. Di Salle, G. Ornati et al. · PubMed · 1992 · 150 citations

Gynecology, Pharmacotherapy, Reproductive Endocrinology +18

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

G Brufman, E Colajori, N. Ghilezan et al. · Annals of Oncology · 1997 · 79 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +8